The first week of September has come and gone and the Renaissance IPO Calendar is beginning to fill up; there were 10 launches, with three companies seeking billion-dollar valuations. Seven companies submitted initial filings, one of which then entered the public market, too.
BELLUS Health (BLU), a Phase 2 biotech based in Quebec, filed, set terms, and priced an upsized $70 million US IPO. The biotech was able to achieve the fast turnaround because it was already listed in Canada. BELLUS Health is developing an oral small molecule therapy for chronic cough, and in July